Smoldering multiple myeloma (SMM) is a plasma cell disorder with the potential to evolve to multiple myeloma.1 Several risk stratification models—commonly, the Mayo Clinic Risk Stratification Model 2008, the Programa para el Tratamiento de Hemopatias Malignas (PETHEMA) model, and the newer Mayo Clinic Risk Stratification Model 2018—have been developed to prognosticate the risk of progression.2,3 These models use clinical variables of disease burden rather than biological tumor characteristics to predict low risk (LR), intermediate risk (IR), and high risk (HR) for progression to multiple myeloma (MM). Multiple clinical trials are investigating the role of treatment in HR SMM. Interpreting the results of clinical trials investigating the role of treatment in HR SMM is problematic owing to variation in the risk stratification criteria used.4 Our study attempts to assess the concordance of these 3 models in a cohort of patients with SMM from 2 clinical trials.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Hill E, Dew A, Morrison C, et al. Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models. JAMA Oncol. 2021;7(1):132–134. doi:10.1001/jamaoncol.2020.5585
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: